Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Current Leases (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Current Leases for 4 consecutive years, with $174000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 1640.0% to $174000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $174000.0, a 1640.0% increase, with the full-year FY2025 number at $174000.0, up 1640.0% from a year prior.
  • Current Leases was $174000.0 for Q4 2025 at Day One Biopharmaceuticals, up from $161000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $462000.0 in Q3 2022 to a low of $10000.0 in Q4 2024.
  • A 4-year average of $267625.0 and a median of $245000.0 in 2024 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: crashed 97.55% in 2024, then soared 1640.0% in 2025.
  • Day One Biopharmaceuticals' Current Leases stood at $405000.0 in 2022, then increased by 0.74% to $408000.0 in 2023, then plummeted by 97.55% to $10000.0 in 2024, then skyrocketed by 1640.0% to $174000.0 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Current Leases are $174000.0 (Q4 2025), $161000.0 (Q3 2025), and $153000.0 (Q2 2025).